MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Up 1.8% - What's Next?

Key Points

• MAIA Biotechnology's stock price increased by 1.8% on Monday, trading between $1.68 and $1.73 during the day, with approximately 386,694 shares exchanged.
• Institutional investors have recently made significant moves in MAIA, with Centric Wealth Management increasing its position by 740.2%, now holding shares valued at over $1 million.
• MAIA Biotechnology is a clinical stage company developing a cancer treatment called THIO, which is currently in a Phase II clinical study for non-small cell lung cancer.

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - )'s share price was up 1.8% during trading on Monday . The stock traded as high as $1.73 and last traded at $1.71. Approximately 386,694 shares were traded during mid-day trading, a decline of 13% from the average daily volume of 445,497 shares. The stock had previously closed at $1.68.

MAIA Biotechnology Price Performance

The firm has a 50-day moving average price of $1.63 and a 200 day moving average price of $1.72. The company has a market cap of $56.41 million, a price-to-earnings ratio of -3.00 and a beta of 0.01.

Hedge Funds Weigh In On MAIA Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in MAIA. Jane Street Group LLC acquired a new position in shares of MAIA Biotechnology in the fourth quarter valued at approximately $77,000. Centerpoint Advisory Group acquired a new position in shares of MAIA Biotechnology in the second quarter valued at approximately $28,000. Geode Capital Management LLC grew its position in shares of MAIA Biotechnology by 3.6% in the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock valued at $400,000 after purchasing an additional 7,746 shares during the last quarter. Centric Wealth Management grew its position in shares of MAIA Biotechnology by 740.2% in the second quarter. Centric Wealth Management now owns 573,398 shares of the company's stock valued at $1,032,000 after purchasing an additional 505,150 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of MAIA Biotechnology in the second quarter valued at approximately $29,000. Institutional investors and hedge funds own 5.65% of the company's stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.